Dynorphin Agonist Therapy of Parkinson's Disease
作者:
M. Giuffra,
M. Mouradian,
T. Davis,
J. Ownby,
T. Chase,
期刊:
Clinical Neuropharmacology
(OVID Available online 1993)
卷期:
Volume 16,
issue 5
页码: 444-447
ISSN:0362-5664
年代: 1993
出版商: OVID
关键词: Neuropeptides;Basal ganglia;Spiradoline
数据来源: OVID
摘要:
SummaryStriatal dynorphin system function may be altered in Parkinson's disease. To evaluate whether treatment with a selective dynorphin agonist improves motor symptoms, four parkinsonian patients received single daily injections of spiradoline under controlled conditions. Doses ranging from 1 to 4 μg/kg had no discernible effect on motor performance when given alone or in combination with levodopa-carbidopa. Three patients developed dose-limiting adverse effects, especially behavioral alterations. These results suggest that dynorphin replacement strategies, using spiradoline-like κ-1 agonists, may have limited value in the therapy of patients with Parkinson's disease.
点击下载:
PDF
(212KB)
返 回